Royal Bank of Canada Has $169.36 Million Holdings in Edwards Lifesciences Co. (NYSE:EW)

Royal Bank of Canada raised its holdings in shares of Edwards Lifesciences Co. (NYSE:EW - Free Report) by 16.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,287,681 shares of the medical research company's stock after acquiring an additional 315,968 shares during the period. Royal Bank of Canada owned approximately 0.39% of Edwards Lifesciences worth $169,358,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. bought a new stake in Edwards Lifesciences during the 4th quarter valued at $26,000. Millstone Evans Group LLC bought a new stake in Edwards Lifesciences during the 4th quarter valued at $29,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in Edwards Lifesciences during the 4th quarter valued at $30,000. Catalyst Capital Advisors LLC bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth $54,000. Finally, SBI Securities Co. Ltd. bought a new stake in shares of Edwards Lifesciences in the 4th quarter worth $62,000. Institutional investors own 79.46% of the company's stock.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, VP Daveen Chopra sold 1,500 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $75.08, for a total value of $112,620.00. Following the completion of the sale, the vice president now owns 33,496 shares of the company's stock, valued at $2,514,879.68. The trade was a 4.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the business's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the sale, the vice president now directly owns 46,936 shares of the company's stock, valued at $3,189,770.56. This represents a 16.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 67,692 shares of company stock worth $4,822,074 over the last 90 days. 1.29% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Barclays boosted their price objective on Edwards Lifesciences from $88.00 to $90.00 and gave the stock an "overweight" rating in a research note on Thursday, February 13th. Evercore ISI dropped their price objective on Edwards Lifesciences from $75.00 to $73.00 and set an "in-line" rating on the stock in a research note on Wednesday, February 12th. Robert W. Baird boosted their price objective on Edwards Lifesciences from $72.00 to $75.00 and gave the stock a "neutral" rating in a research note on Thursday, April 24th. Morgan Stanley boosted their price objective on Edwards Lifesciences from $70.00 to $75.00 and gave the stock an "equal weight" rating in a research note on Wednesday, February 12th. Finally, Citigroup reissued a "buy" rating and issued a $95.00 price objective (up previously from $84.00) on shares of Edwards Lifesciences in a research note on Thursday. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating and eleven have given a buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Hold" and a consensus target price of $80.20.

Edwards Lifesciences Stock Up 0.3%

Shares of EW stock traded up $0.19 on Friday, reaching $74.98. 3,738,140 shares of the company's stock traded hands, compared to its average volume of 5,138,901. Edwards Lifesciences Co. has a 12-month low of $58.93 and a 12-month high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46. The company has a market capitalization of $43.98 billion, a P/E ratio of 10.76, a price-to-earnings-growth ratio of 4.82 and a beta of 1.12. The business's 50 day moving average price is $72.78 and its two-hundred day moving average price is $72.04.

Edwards Lifesciences (NYSE:EW - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.60 by $0.04. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business had revenue of $1.41 billion for the quarter, compared to the consensus estimate of $1.40 billion. During the same quarter in the previous year, the company posted $0.66 earnings per share. Edwards Lifesciences's revenue for the quarter was up 6.2% compared to the same quarter last year. On average, equities analysts forecast that Edwards Lifesciences Co. will post 2.45 earnings per share for the current year.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.